MedTrace Logo

A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis

NCT04189705 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 392

Last updated 2021-03-11

No results posted yet for this study

Summary

This is a multi-center, randomized, double-blind, active-controlled, non-inferiority, phase 3 study to evaluate the efficacy and safety of MCT-SR in patients with gastritis.

Conditions

  • Acute Gastritis
  • Chronic Gastritis

Interventions

DRUG

MCT-SR

Rebamipide 150mg

DRUG

Mucosta Tab.

Rebamipide 100mg

Sponsors & Collaborators

  • Korea Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • JaeGyu Kim, Ph.D. · Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-30
Primary Completion
2020-04-23
Completion
2020-04-23

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04189705 on ClinicalTrials.gov